Takeda Pharmaceutical Company Limited (TKDA) - Net Assets
Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) has net assets worth €7.64 Trillion EUR (≈ $8.94 Trillion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€15.41 Trillion ≈ $18.01 Trillion USD) and total liabilities (€7.76 Trillion ≈ $9.08 Trillion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Takeda Pharmaceutical Company Limited (TKDA) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.64 Trillion |
| % of Total Assets | 49.61% |
| Annual Growth Rate | 17.2% |
| 5-Year Change | 33.97% |
| 10-Year Change | N/A |
| Growth Volatility | 50.44 |
Takeda Pharmaceutical Company Limited - Net Assets Trend (2017–2025)
This chart illustrates how Takeda Pharmaceutical Company Limited's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Takeda Pharmaceutical Company Limited to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual net assets of Takeda Pharmaceutical Company Limited from 2017 to 2025. For live valuation and market cap data, see market cap of Takeda Pharmaceutical Company Limited.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €6.94 Trillion ≈ $8.11 Trillion |
-4.65% |
| 2024-03-31 | €7.27 Trillion ≈ $8.50 Trillion |
+14.47% |
| 2023-03-31 | €6.35 Trillion ≈ $7.43 Trillion |
+11.81% |
| 2022-03-31 | €5.68 Trillion ≈ $6.64 Trillion |
+9.78% |
| 2021-03-31 | €5.18 Trillion ≈ $6.05 Trillion |
+9.51% |
| 2020-03-31 | €4.73 Trillion ≈ $5.53 Trillion |
-8.45% |
| 2019-03-31 | €5.16 Trillion ≈ $6.04 Trillion |
+155.95% |
| 2018-03-31 | €2.02 Trillion ≈ $2.36 Trillion |
+3.51% |
| 2017-03-31 | €1.95 Trillion ≈ $2.28 Trillion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Takeda Pharmaceutical Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.19 Trillion | 17.12% |
| Other Components | €5.75 Trillion | 82.88% |
| Total Equity | €6.94 Trillion | 100.00% |
Takeda Pharmaceutical Company Limited Competitors by Market Cap
The table below lists competitors of Takeda Pharmaceutical Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CTBC Financial Holding Co Ltd
TW:2891
|
$43.71 Billion |
|
East Money Information Co Ltd
SHE:300059
|
$43.73 Billion |
|
Itaú Unibanco Holding S.A.
SA:ITUB3
|
$43.98 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
$44.06 Billion |
|
Ambev S.A.
F:AMNA
|
$43.57 Billion |
|
LG Electronics Inc
KO:066570
|
$43.33 Billion |
|
Doosan Heavy Ind. & Const.
KO:034020
|
$43.31 Billion |
|
STANDARD CHART.UNSP.ADR/2
F:STD0
|
$43.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Takeda Pharmaceutical Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,273,264,000,000 to 6,935,084,000,000, a change of -338,180,000,000 (-4.6%).
- Net income of 107,928,000,000 contributed positively to equity growth.
- Dividend payments of 302,498,000,000 reduced retained earnings.
- Share repurchases of 51,860,000,000 reduced equity.
- Other factors decreased equity by 91,750,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €107.93 Billion | +1.56% |
| Dividends Paid | €302.50 Billion | -4.36% |
| Share Repurchases | €51.86 Billion | -0.75% |
| Other Changes | €-91.75 Billion | -1.32% |
| Total Change | €- | -4.65% |
Book Value vs Market Value Analysis
This analysis compares Takeda Pharmaceutical Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €2425.92 | €12.90 | x |
| 2018-03-31 | €2556.51 | €12.90 | x |
| 2019-03-31 | €3318.53 | €12.90 | x |
| 2020-03-31 | €3032.22 | €12.90 | x |
| 2021-03-31 | €3308.75 | €12.90 | x |
| 2022-03-31 | €3665.61 | €12.90 | x |
| 2023-03-31 | €4087.49 | €12.90 | x |
| 2024-03-31 | €4635.57 | €12.90 | x |
| 2025-03-31 | €4407.01 | €12.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Takeda Pharmaceutical Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.36%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 2.05x
- Recent ROE (1.56%) is below the historical average (4.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 6.07% | 6.64% | 0.40x | 2.30x | €-74.49 Billion |
| 2018 | 9.36% | 10.56% | 0.43x | 2.06x | €-12.86 Billion |
| 2019 | 2.12% | 5.20% | 0.15x | 2.69x | €-406.83 Billion |
| 2020 | 0.94% | 1.34% | 0.26x | 2.71x | €-428.11 Billion |
| 2021 | 7.27% | 11.76% | 0.25x | 2.50x | €-141.30 Billion |
| 2022 | 4.05% | 6.45% | 0.27x | 2.32x | €-338.24 Billion |
| 2023 | 4.99% | 7.87% | 0.29x | 2.20x | €-318.40 Billion |
| 2024 | 1.98% | 3.38% | 0.28x | 2.08x | €-583.26 Billion |
| 2025 | 1.56% | 2.36% | 0.32x | 2.05x | €-585.58 Billion |
Industry Comparison
This section compares Takeda Pharmaceutical Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,817,214,049
- Average return on equity (ROE) among peers: -32.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited (TKDA) | €7.64 Trillion | 6.07% | 1.02x | $43.60 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $59.93 Billion | 4.62% | 0.96x | $1.19 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $7.85 Billion | 28.40% | 0.37x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $4.89 Million | -63.10% | 0.49x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-9.91 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $17.35 Million | -23.30% | 0.22x | $13.93 Million |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $72.84 Million |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more